Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PCR. Found 6 abstracts

Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Research. 2007 Sep;67(18):8433-8.
Coudry RA, Meireles SI, Stoyanova R, Cooper HS, Carpino A, Wang XQ, Engstrom PF, Clapper ML. Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. Journal of Molecular Diagnostics. 2007 Feb;9(1):70-9.
Cairns PG. Methods for detecting hypermethylated promoters of tumor suppressor genes associated with ovarian cancer using methylation-specific PCR. 2006 Sep 14;:28 pp.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
Einarson MB, Estojak J, Serebriiskii I, Golemis EA. HEI-C encoding nucleic acids, polypeptides, antibodies and methods of uses thereof. 2001 Jun 20;:83 pp.
Reichman-Fried M, Bosma MJ, Hardy RR. B-lineage cells in ?-transgenic scid mice proliferate in response to IL-7 but fail to show evidence of immunoglobulin light chain gene rearrangement. International Immunology. 1993 Jan;5(3):303-10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PCR

PCR Human RNA interleukin 7 DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (BRCA1 treated and monitored prospectively mL) polypeptides cDNA sequences (HEI-C encoding nucleic acids-antibodies and methods of uses thereof) Test kits the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint POLYMERASE CHAIN-REACTION combined immunodeficiency but did not meet all of Prentice's significantly associated with CSS lymphocyte proliferation methods for detecting hypermethylated promoters of tumor suppressor genes assocd with ovarian cancer using methylation-specific PCR) B cell development NONCARRIERS GENE-EXPRESSION ANALYSIS Oligonucleotides Blood plasma Ascitic fluid Protein motifs (of HEI-C protein the randomized treatment DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (APC b lymphocyte Epitopes BSU (Biological study Probes Role: ARG (Analytical reagent use)-unclassified)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (HEI-C encoding nucleic acids-polypeptides-antibodies and methods of uses thereof) GENE-EXPRESSION RISK BSU (Biological study Primers Role: ARG (Analytical reagent use)-unclassified)-THU (Therapeutic use)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (HEI-C encoding nucleic acids-polypeptides-antibodies and methods of uses thereof) Neoplasm OVARIAN-CANCER RISK AB (Purpose:) under bar We evaluated whether posttreatment DGN (Diagnostic use) Genetic element Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (CpG island Gleason score and PSA stage-all of Prentice's requirements were not hypermethylation promoter tumor suppressor genes ovarian cancer PCR diagnosis AMPLIFICATION WOMEN time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier Flow cytometry DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (CDKN2A Diagnosis (mol Cell nucleus Drug screening Immobilization DGN (Diagnostic use) Promoter Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (methods for detecting hypermethylated promoters of tumor suppressor genes assocd with ovarian cancer using methylation-specific PCR) gene rearrangement Blood serum (anal GENE HUMAN CANCER RADICAL PROSTATECTOMY polypeptides HEI-C encoding nucleic acids-antibodies and methods of uses thereof) Inc prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a Scid mice unclassified) Signal peptides Role: BSU (Biological study-BIOL (Biological study) (HEI-C encoding nucleic acids-polypeptides-antibodies and methods of uses thereof) (Results: ) under bar After a median follow-up time of 59 years PSA measurements) and cancer-specific survival (CSS) DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (DAP-kinase Diagnosis (cancer FAILURE Genetic polymorphism Ig transgene Nucleic acid amplification MORTALITY human gene HEIC protein cDNA sequence immunoglobulin light chain Protein sequences unclassified) mRNA Role: BSU (Biological study-BIOL (Biological study) (HEI-C expression unclassified) Antibodies Role: BSU (Biological study-BIOL (Biological study) (monoclonal 514 men with localized prostate cancer measurements in a cohort of 1 Nucleic acid hybridization Transcription (HEI-C RECURRENCE (T2c-4 and PSA level < 150 ng DEATH we tested if PSADT was prognostic and Cox proportional hazards model (Conclusions) under bar Prostatic specific antigen doubling time is DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (RASSF1A methylation specific PCR ovary cancer diagnosis ARRAYS Genetic mapping (restriction DNA (P-Cox = 04) The significant posttreatment PSADTs were also Blood analysis EPIDEMIOLOGY Alleles PCR cancer diagnosis drug kit human Ig rearrangement HISTORY DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (tumor suppressor independent of randomized treatment in this cohort The endpoints were significant predictors of CSS (P-Cox < 0001) After adjusting for T Methylation Tumor markers (methods for detecting hypermethylated promoters of tumor suppressor genes assocd with ovarian cancer using methylation-specific PCR) Ovary Mutation unclassified) Genetic element Role: BSU (Biological study-BIOL (Biological study) (exon-HEI-C gene DNA sequence analysis (Methods and Materials: ) under bar We analyzed posttreatment PSA Drugs or in combination with 24 65-70 Gy of radiation therapy (n = 761) DGN (Diagnostic use) Gene Role: ANT (Analyte)-ANST (Analytical study)-BIOL (Biological study)-USES (Uses) (p14ARF Test kits (diagnostic formation Animal tissue (aberrant PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < unclassified) Proteins Role: BSU (Biological study-BIOL (Biological study) (MAP (microtubule-assocd protein)-HEI-C unclassified) Gene Role: BSU (Biological study-PRP (Properties)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (HEI-C and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) randomized treatment was a significant predictor for CSS (p(Cox) = months of adjuvant androgen deprivation (n = 753) Using an adjusted of HEI-C Coiled-coil (domain Post-translational processing Antibodies Molecular cloning men were randomized to neoadjuvant androgen deprivation and April 1995 Gel electrophoresis (non denaturing Susceptibility (to cancer
Last updated on Thursday, July 16, 2020